The bone substitute and allograft bone market is valued at USD 3.1 billion in 2021 and is poised to grow at a significant CAGR of 6.1% over 2022–2028. The growing use of grafts in dental operations is expected to generate profitable growth prospects for the market players during the forecast period. Rising demand for dental bone grafts and technological advances propel the market forward. Increased investment in R&D by key players in bone grafts and their substitutes and an increase in incidences of orthopedic operations among the elderly are projected to generate significant growth for market players over the forecast period. Introducing novel polymer and ceramic materials with biologically superior features is one of the market’s essential developments. New manufacturing technologies like fast prototyping and 3D printing assist in the manufacture of free-form biomaterial scaffolds for tissue regeneration. Furthermore, increased morbidity rates, a growing geriatric population, and an increase in occurrences of osteoarthritis are driving up demand for bone grafts and substitutes. Apart from that, the market is being bolstered by a shift toward minimally invasive procedures and a growing awareness among patients about the benefits of biologic bone regeneration. The availability of improved products in various forms and sizes, the rising frequency of orthopedic difficulties and periodontal disorders, and the growing number of studies examining the enhancement of bioactivity of bone graft substitutes are some of the other growth-inducing aspects. To maintain the market position in the competition, key players worldwide employ various techniques in the bone graft substitutes market. Companies are concentrating on launching sophisticated products and strengthening their distribution channels. Moreover, numerous companies in the global bone graft replacements market are investing in research to develop high-efficiency materials. For instance, in January 2021, Dentsply Sirona acquired Datum Dental Ltd., a company recognized for its unique dental regeneration solutions. Dentsply Sirona promotes the whole OSSIX portfolio in the United States, Canada, and several other countries, including OSSIX Plus, OSSIX Volumax, and OSSIX Bone.
Recent Market Developments:
In January 2020, Orthopeaditrics Corp. introduced a synthetic bone graft substitute in the United States called QuickPack. It is highly viscous and contains calcium phosphate cement that closely resembles the mineral phase of a bone.
In March 2022, Fredun Pharmaceuticals Limited received approval to manufacture Xenografts for various dental and orthopedic surgical appliances from the Central Drugs Standard Control Organisation (COSCO), India.